Known targets — ChEMBL curated mechanism
ADRA1AHTR2AHTR2CHTR3AHTR3BHTR3CHTR3DHTR3ESLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Tedatioxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 9/20 | 0.54 |
| ▸ | HTR3A known ✓ | P46098 | 4/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tedatioxetine SCHEMBL3930077 | 0.98 | HTR2C (0.55) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| Tedatioxetine SCHEMBL1741722 | 0.98 | HTR2C (0.53) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3539172 | 0.87 | HTR2C (0.51) | HTR2CHTR1AHTR3ASLC6A2SLC6A4 | |
| SCHEMBL27902510 | 0.87 | HTR2C (0.53) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3541318 | 0.85 | HTR1A (0.54) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3544140 | 0.85 | HTR1A (0.52) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL19962179 | 0.84 | CYP3A4 (0.42) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3546046 | 0.84 | HTR1A (0.56) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3546519 | 0.84 | HTR1A (0.55) | HTR2CHTR1AHTR3ASLC6A2SLC6A4 | |
| SCHEMBL2469257 | 0.81 | HTR2C (0.67) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-11969431-B2 | Formulations for treatment of post-traumatic stress disorder | GLYTECH LLC (US) | 2024-04-30 | — | — | US | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-2564837-B1 | ENTERIC TABLET | TAKEDA PHARMACEUTICALS CO (JP) | 2019-01-30 | — | — | EP | claimed |
| US-20180127389-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | H. LUNDBECK A/S (DK) | 2018-05-10 | — | — | US | claimed |
| US-20180072690-A1 | Methods for Making Serotonin Reuptake Inhibitors | CIPLA LIMITED (IN) | 2018-03-15 | — | — | US | claimed |
| EP-3274330-A1 | METHOD FOR MAKING SEROTONIN REUPTAKE INHIBITORS | Cipla Limited (IN) | 2018-01-31 | — | — | EP | claimed |
| US-20170087138-A1 | Therapeutic Uses Of Compounds Having Affinity To The Serotonin Transporter, Serotonin Receptors And Noradrenalin Transporter | H LUNDBECK AS (DK) | 2017-03-30 | — | — | US | claimed |
| WO-2008113358-A1 | LIQUID FORMULATIONS OF SALTS OF 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE | H. LUNDBECK A/S (DK) | 2008-09-25 | — | — | WO | claimed |
| WO-2008113360-A2 | 4- [2- (4-METHYLPHENYLSULFANYD-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION | H. LUNDBECK A/S (DK) | 2008-09-25 | — | — | WO | claimed |
| WO-2007144006-A1 | CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | H. LUNDBECK A/S (DK) | 2007-12-21 | — | — | WO | claimed |
| US-20070060574-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2007-03-15 | — | — | US | claimed |
| EP-1749818-A2 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. Lundbeck A/S (DK) | 2007-02-07 | — | — | EP | claimed |
| US-7148238-B2 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2006-12-12 | — | — | US | claimed |
| US-20060089368-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2006-04-27 | — | — | US | claimed |
| US-20050014740-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2005-01-20 | — | — | US | claimed |
| EP-1436271-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2004-07-14 | — | — | EP | claimed |
| WO-2003029232-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072690-A1 | Methods for Making Serotonin Reuptake Inhibitors | SLC6A4, SLC6A2, SLC6A3 | HTR2C 15/4885HTR3A 7/4885SLC6A2 2/4885 |
| US-20060089368-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | TPH1, HTR5A, HTR2C | HTR2C 3/4885HTR3A 9/4885SLC6A2 21/4885 |
| US-20050014740-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | TPH1, HTR5A, HTR2C | HTR2C 3/4885HTR3A 9/4885SLC6A2 21/4885 |
| US-20180127389-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | TPH1, HTR5A, HTR2C | HTR2C 3/4885HTR3A 9/4885SLC6A2 21/4885 |
| US-20170087138-A1 | Therapeutic Uses Of Compounds Having Affinity To The Serotonin Transporter, Serotonin Receptors And Noradrenalin Transporter | SLC6A2, SLC6A4, SLC18A2 | HTR2C 23/4885HTR3A 13/4885SLC6A2 1/4885 |
| US-20070060574-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | TPH1, HTR5A, HTR2C | HTR2C 3/4885HTR3A 9/4885SLC6A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.